(Q36646150)

15 August 2017

1 reference

title

Interferon and other biologic agents for the treatment of Kaposi's sarcoma (English)

1 reference

15 August 2017

Interferon and Other Biologic Agents for the Treatment of Kaposi's Sarcoma (English)

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

4 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

4 November 2022

author name string

S. E. Krown

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1708760

4 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1708760

4 November 2022

publication date

1 April 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:S088985881830443X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

https://api.elsevier.com/content/article/PII:S088985881830443X?httpAccept=text/plain

4 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Hematology / Oncology Clinics of North America

4 November 2022

published in

1 reference

15 August 2017

5

1 reference

15 August 2017

2

1 reference

15 August 2017

311-322

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

15 August 2017

3

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

4 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC)

4 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

4 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California

4 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters

4 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Herpes-Type Virus Particles in Tissue Culture of Kaposi's Sarcoma From Different Geographic Regions2

4 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Antibody patterns to herpesviruses in Kaposi's sarcoma. II. Serological association of american Kaposi's sarcoma with cytomegalovirus

4 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Antibody patterns to herpesviruses in kaposi's sarcoma: Serological association of european kaposi's sarcoma with cytomegalovirus

4 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome

4 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon.

4 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma in recipients of renal transplants

4 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

4 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A

4 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma

4 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Idiopathisches multiples Pigmentsarkom der Haut

4 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interferon alpha in the treatment of AIDS-associated Kaposi's sarcoma

4 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi Sarcoma complicating systemic lupus erythematosus treated with immunosuppression

4 November 2022

27

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)

4 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Therapeutic trial of interferon-gamma in patients with epidemic Kaposi's sarcoma

4 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS)

4 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee

4 November 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma

4 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

4 November 2022

39

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial

4 November 2022

40

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

4 November 2022

43

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections

4 November 2022

45

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Site-specific mutagenesis of the human fibroblast interferon gene

4 November 2022

46

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study

4 November 2022

47

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Treatment of immunodeficiency with interleukin-2: initial exploration

4 November 2022

48

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections

4 November 2022

51

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy

4 November 2022

52

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interferon-gamma, the activated macrophage, and host defense against microbial challenge

4 November 2022

54

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome

4 November 2022

55

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma in organ transplant recipients: report of 20 cases

4 November 2022

57

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Effect of Interferon on Murine Leukaemia Virus Infection. IV. Formation of Non-infectious Virus in Chronically Infected Cells

4 November 2022

58

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines

4 November 2022

59

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Spontaneous regression of Kaposi's sarcoma in patients with AIDS

4 November 2022

61

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon

4 November 2022

62

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon

4 November 2022

64

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

4 November 2022

65

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Kaposi's sarcoma: a review and recent developments

4 November 2022

68

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro.

4 November 2022

69

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Interleukin-2 in the treatment of HIV disease

4 November 2022

71

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice

4 November 2022

76

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1.

4 November 2022

77

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Therapy of acquired immune deficiency syndrome with recombinant interleukin-2.

4 November 2022

78

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A)

4 November 2022

79

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30443-X

4 November 2022

Identifiers

1 reference